WLF DEPOSITION OF FDA COMMISSIONER KESSLER IS JUSTIFIED BY "DIRECT" INVOLVEMENT WITH CME POLICY, FOUNDATION ARGUES; COURT RULING ON ISSUE EXPECTED IN MAY
This article was originally published in The Gray Sheet
FDA Commissioner David Kessler's "direct, active role" in formulating the agency's draft policy on industry-sponsored continuing medical education makes him eligible for deposition, the Washington Legal Foundation says in a motion recently filed in the U.S. District Court for the District of Columbia as part of its suit against the policy. The motion says that "given Dr. Kessler's intimate personal involvement in the issues giving rise to this suit, WLF is entitled to question him regarding his knowledge of those issues."
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.